Brought to you by 
Merck Serono takes an option to license Opexa's MS candidate Tcelna
08 Oct 2021
Executive Summary
Opexa Therapeutics Inc. (developing treatments for autoimmune diseases) has granted Merck Serono SA an exclusive option to license its multiple sclerosis candidate Tcelna (imilecleucel-T) worldwide, excluding Japan.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck Serono takes an option to license Opexa's MS candidate Tcelna
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice